Comparison of three protracted antiemetic regimens for the control of delayed emesis in cisplatin-treated patients

Eur J Cancer. 1992;28A(8-9):1344-7. doi: 10.1016/0959-8049(92)90515-4.

Abstract

Antiemetic activity of three protracted regimens for the control of cisplatin-evoked delayed emesis was explored. 63 patients were randomly assigned to receive one of three protracted antiemetic schedules over 4 days. Group C patients received dexamethasone 8 mg twice daily on days 2 and 3, then 4 mg twice daily on days 4 and 5; in group B, alizapride 2.5 mg/kg four times daily on days 2-5 plus dexamethasone as in group C was administered; and in group A, metoclopramide 0.5 mg/kg four times daily on days 2-5 plus dexamethasone was given at the same dose-schedule as in groups C and B. Complete protection from delayed vomiting was achieved in 44% of group C, 30% of B and 70% of group A (P = 0.02). Mild side-effects were noted in all three groups. A higher complete protection for delayed emesis was obtained in metoclopramide-dexamethasone-treated patients. Neither of the regimens used in the protection of delayed emesis controlled late nausea.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Antiemetics / therapeutic use*
  • Cisplatin / adverse effects*
  • Dexamethasone / therapeutic use
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Female
  • Humans
  • Male
  • Metoclopramide / therapeutic use
  • Middle Aged
  • Pyrrolidines / therapeutic use
  • Single-Blind Method
  • Time Factors
  • Vomiting / chemically induced*

Substances

  • Antiemetics
  • Pyrrolidines
  • Dexamethasone
  • Metoclopramide
  • alizapride
  • Cisplatin